A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus
Crossref DOI link: https://doi.org/10.1007/s12020-017-1341-2
Published Online: 2017-06-07
Published Print: 2017-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hohendorff, J.
Szopa, M.
Skupien, J.
Kapusta, M.
Zapala, B.
Platek, T.
Mrozinska, S.
Parpan, T.
Glodzik, W.
Ludwig-Galezowska, A.
Kiec-Wilk, B.
Klupa, T.
Malecki, M. T.
License valid from 2017-06-07